• Users Online: 148
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2021  |  Volume : 32  |  Issue : 4  |  Page : 164-170

Comparison of trimodal therapy versus radical cystectomy for each stage of muscle-invasive bladder cancer


1 Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan
2 Division of Urology, Department of Surgery, Chi Mei Medical Center; Chia Nan University of Pharmacy and Science, Tainan, Taiwan
3 Division of Neurosurgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan
4 Division of Urology, Department of Surgery, Chi Mei Hospital, Tainan, Taiwan
5 Department of Urology, Mackay Memorial Hospital; School of Medicine, National Yang-Ming University, Taipei, Taiwan

Correspondence Address:
Dr. Steven K Huang
Division of Urology, Department of Surgery, Chi Mei Medical Center, No. 901, Zhonghua Road, Yongkang, Tainan 710
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/UROS.UROS_8_21

Rights and Permissions

Purpose: Radical cystectomy (RC) has long been the standard of care for the management of muscle-invasive bladder cancer (MIBC). However, an increasing trend of bladder-sparing trimodal therapy (TMT) using maximal transurethral resection of bladder tumor, followed by radiation therapy (RT) with concomitant radiosensitizing chemotherapy, has been advocated. We compared the differences regarding long-term oncological outcomes between patients who accepted RC or TMT for MIBC. Materials and Methods: Between January 2012 and December 2018, 207 patients were diagnosed with MIBC at our center. We excluded patients with metastasis disease, received other treatments, and lost to follow-up. The patients were categorized into Group 1 (TMT) and Group 2 (RC). Both the groups with each tumor stage were compared for disease-free survival (DFS) and overall survival (OS) rates, and the risk factors for recurrence and survival were assessed. Results: In total, 58 (48.7%) patients in Group 1 underwent TMT and 61 (51.3%) patients in Group 2 underwent RC. The mean follow-up was 39.8 months. The 3-year DFS rates were 44.1% and 69.7% for Groups 1 and 2, respectively (P = 0.003). The 3-year OS rates were 61.7% and 72.5% for Groups 1 and 2, respectively (P = 0.226). We also analyzed the DFS with each stage, and the results showed a lower DFS rate for T2 and N0 stages. Conclusion: There was no significant survival benefit for MIBC with either RC or TMT. However, RC is associated with better outcome of DFS rate, especially for patients with early stages of MIBC in stages T2 and N0.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1478    
    Printed2    
    Emailed0    
    PDF Downloaded210    
    Comments [Add]    

Recommend this journal